1. Home /
  2. Marijuana

Marijuana

Cowen Says Tilray Is Still a Buy Despite Spate of Underwhelming Pot Earnings

Cowen Says Tilray Is Still a Buy Despite Spate of Underwhelming Pot Earnings

Cowen lowers Tilray's price target but maintains its 'outperform' rating.

Canopy Growth Slides After Quarterly Revenue Misses Estimates

Canopy Growth Slides After Quarterly Revenue Misses Estimates

Canopy Growth's fiscal second-quarter revenue misses analysts' estimates.

Tilray Slips as Revenue Misses and EPS Is a Little Better Than Estimates

Tilray Slips as Revenue Misses and EPS Is a Little Better Than Estimates

Tilray shares are falling after reporting mixed third-quarter results.

Cronos Swings to Loss Despite Revenue Spike, Stock Falls

Cronos Swings to Loss Despite Revenue Spike, Stock Falls

Cronos sells 213% more cannabis by kilograms in the third quarter than it did a year ago.

How This Former VC Player Became CEO of $2 Billion Cannabis Company Tilray

How This Former VC Player Became CEO of $2 Billion Cannabis Company Tilray

With Tilray set to report earnings after today's closing bell, we're rewinding to our sit-down with CEO Brendan Kennedy.

Aurora Cannabis Tanks Despite Strong Earnings Growth

Aurora Cannabis Tanks Despite Strong Earnings Growth

Aurora Cannabis reports fiscal first-quarter revenue growth of 260%.

Jim Cramer's Take on the Cannabis Craze

Jim Cramer's Take on the Cannabis Craze

Another cannabis craze?

IGC, Tilray and Other Pot Stocks Gain After Sessions Quits as Attorney General

IGC, Tilray and Other Pot Stocks Gain After Sessions Quits as Attorney General

IGC and Tilray rise by double-digit percentages and other weed stocks rally as anti-pot attorney general steps down and voters back cannabis sales in three states.

Pot Stocks Pop After Michigan Legalizes Recreational Cannabis Use

Pot Stocks Pop After Michigan Legalizes Recreational Cannabis Use

Michigan becomes the 10th U.S. state to legalize the recreational use of marijuana.

CV Sciences CEO on the Future of CBD in Healthcare

CV Sciences CEO on the Future of CBD in Healthcare

CV Sciences CEO discusses the medical applications of CBD at Jim Cramer's teach in.